[Antiplatelet agents and their therapeutic use].
Antiplatelet agents have a well established effect against thrombosis complicating atherosclerosis. Drugs currently in use in France are: aspirin and flurbiprofen, inhibiting thromboxane synthesis; ticlopidine and clopidogrel, inhibiting platelet activation by adenosine diphosphate; dipyridamole, inhibiting platelet activation through adenosine; abciximab, acting on the mechanism of aggregation. Their molecular and cellular pharmacology is in agreement with the clinical effects and the guidelines for practical use. These drugs have in common that they carry a risk of hemorrhage, albeit low but difficult to cope with in case of invasive procedures. There is no antidote. They also have specific contraindications. No laboratory tests aimed at assessing their effect on primary haemostasis are proved of any clinical value.
Lecompte
T
T
CHU de Nancy.
D001161:Arteriosclerosis / Q000150:complications; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000188:drug therapy*
D010975:Platelet Aggregation Inhibitors
Médicaments antiplaquettaires et leur maniement.